Phase II, Open-label Study of Erlotinib (Tarceva) Treatment in Patients With Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor

Trial Profile

Phase II, Open-label Study of Erlotinib (Tarceva) Treatment in Patients With Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 14 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 May 2013 Planned end date changed from 1 May 2016 to 1 Nov 2014 as reported by ClinicalTrials.gov.
    • 23 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top